Skip to main content

Publications

Found 81 results
Author [ Title(Asc)] Year
Filters: Author is Laura A Magee  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
P
Duffy J, Hooft Jvan 't, Gale C, Brown M, Grobman W, Fitzpatrick R, et al.. A protocol for developing, disseminating, and implementing a core outcome set for pre-eclampsia. Pregnancy Hypertens. 2016;6(4):274-278.  (336.66 KB)
Payne BA, von Dadelszen P, Bhutta ZA, Magee LA, Olalekan A, Sotunsa J, et al.. Protocol 13PRT/9313:The Community Level Interventions for Pre-eclampsia (CLIP) Trials: four prospective cluster randomised controlled trials comparing a package of interventions directed towards improving maternal and perinatal outcomes related to pre-ecl [Internet]. 2019 . https://clinicaltrials.gov/ct2/show/study/NCT01911494?term=01911494&rank=1
Sharma S, Olalekan A, Vidler M, Drebit S, Payne BA, Akeju D, et al.. A process evaluation plan for assessing a complex community-based maternal health intervention in Ogun State, Nigeria. BMC Health Serv Res. 2017;17(1):238.  (925.17 KB)
Magee LA, von Dadelszen P. Prevention and treatment of postpartum hypertension. Cochrane Database Syst Rev. 2013;(4):CD004351.  (447.63 KB)
von Dadelszen P, Magee LA. Preventing deaths due to the hypertensive disorders of pregnancy. Best Pract Res Clin Obstet Gynaecol. 2016;36:83-102.  (389.82 KB)
von Dadelszen P, Sawchuck D, Hofmeyr J, Magee LA, Bracken H, Mathai M, et al.. PRE-EMPT (PRE-eclampsia-Eclampsia Monitoring, Prevention and Treatment): A low and middle income country initiative to reduce the global burden of maternal, fetal and infant death and disease related to pre-eclampsia. Pregnancy Hypertens. 2013;3(4):199-202.  (183.96 KB)
von Dadelszen P, Firoz T, Donnay F, Gordon R, Hofmeyr J, Lalani S, et al.. Preeclampsia in low and middle income countries-health services lessons learned from the PRE-EMPT (PRE-Eclampsia-Eclampsia Monitoring, Prevention and Treatment) project. J Obstet Gynaecol Can. 2012;34(10):917-926.  (322.96 KB)
von Dadelszen P, Magee LA. Pre-eclampsia: an update. Curr Hypertens Rep. 2014;16(8):454.  (486.35 KB)
Mol B, Roberts C, Thangaratinam S, Magee LA, de Groot C, Hofmeyr J. Pre-eclampsia. Lancet. 2016;387(10022):999-1011.  (128.83 KB)
von Dadelszen P, Payne BA, Li J, Ansermino JM, F Pipkin B, Côté A-M, et al.. Prediction of adverse maternal outcomes in pre-eclampsia: development and validation of the fullPIERS model. Lancet. 2011;377(9761):219-27.  (201.46 KB)
Ukah V, De Silva D, Payne BA, Magee LA, Hutcheon J, Brown H, et al.. Prediction of adverse maternal outcomes from pre-eclampsia and other hypertensive disorders of pregnancy: A systematic review. Pregnancy Hypertens. 2018;11:115-123.  (501.41 KB)
Akkermans J, Payne BA, von Dadelszen P, Groen H, de Vries J, Magee LA, et al.. Predicting complications in pre-eclampsia: external validation of the fullPIERS model using the PETRA trial dataset. Eur J Obstet Gynecol Reprod Biol. 2014;179:58-62.  (317.15 KB)
Makanga P, Sacoor C, Schuurman N, Lee T, Vilanculo F, Munguambe K, et al.. Place-specific factors associated with adverse maternal and perinatal outcomes in Southern Mozambique: a retrospective cohort study. BMJ Open. 2019;9(2):e024042.  (2.94 MB)
Ukah V, Hutcheon J, Payne BA, Haslam M, Vatish M, Ansermino JM, et al.. Placental Growth Factor as a Prognostic Tool in Women With Hypertensive Disorders of Pregnancy: A Systematic Review. Hypertension. 2017;70(6):1228-1237.  (986.49 KB)
Benton S, McCowan L, Heazell AEP, Grynspan D, Hutcheon J, Senger C, et al.. Placental growth factor as a marker of fetal growth restriction caused by placental dysfunction. Placenta. 2016;42:1-8.  (475.29 KB)
Payne BA, Magee LA, Côté A-M, Hutcheon J, Li J, Kyle PM, et al.. PIERS proteinuria: relationship with adverse maternal and perinatal outcome. J Obstet Gynaecol Can. 2011;33(6):588-597.  (292.91 KB)
Payne BA, Magee LA, Côté A-M, Hutcheon J, Li J, Kyle PM, et al.. PIERS proteinuria: relationship with adverse maternal and perinatal outcome. J Obstet Gynaecol Can. 2011;33(6):588-597.  (292.91 KB)
Firoz T, Magee LA, Payne BA, Menzies J, von Dadelszen P. The PIERS experience: research or quality improvement?. J Obstet Gynaecol Can. 2012;34(4):379-81.  (233.18 KB)
Lalani S, Firoz T, Magee LA, Sawchuck D, Payne BA, Gordon R, et al.. Pharmacotherapy for preeclampsia in low and middle income countries: an analysis of essential medicines lists. J Obstet Gynaecol Can. 2013;35(3):215-223.  (529.81 KB)
Payne BA, Hodgson S, Hutcheon J, Joseph KS, Li J, Lee T, et al.. Performance of the fullPIERS model in predicting adverse maternal outcomes in pre-eclampsia using patient data from the PIERS (Pre-eclampsia Integrated Estimate of RiSk) cohort, collected on admission. BJOG. 2013;120(1):113-8.  (85.31 KB)
M
Aarvold A, Ryan H, Magee LA, von Dadelszen P, Fjell C, Walley K. Multiple Organ Dysfunction Score Is Superior to the Obstetric-Specific Sepsis in Obstetrics Score in Predicting Mortality in Septic Obstetric Patients. Crit Care Med. 2017;45(1):e49-e57.  (910.16 KB)
von Dadelszen P, Magee LA, Payne BA, Dunsmuir D, Drebit S, Dumont G, et al.. Moving beyond silos: How do we provide distributed personalized medicine to pregnant women everywhere at scale? Insights from PRE-EMPT. Int J Gynaecol Obstet. 2015;131 Suppl 1:S10-5.  (662.6 KB)
Firoz T, Chou D, von Dadelszen P, Agrawal P, Vanderkruik R, Tunçalp Ö, et al.. Measuring maternal health: focus on maternal morbidity. Bull World Health Organ. 2013;91(10):794-6.  (660.26 KB)
Bellad M, Vidler M, Honnungar N, A M, Ramadurg U, Charanthimath U, et al.. Maternal and Newborn Health in Karnataka State, India: The Community Level Interventions for Pre-Eclampsia (CLIP) Trial's Baseline Study Results. PLoS One. 2017;12(1):e0166623.  (2.12 MB)
Houlihan S, Decarie D, Benes C, Cleve R, Vidler M, Magee LA, et al.. Magnocaine: Physical Compatibility and Chemical Stability of Magnesium Sulphate and Lidocaine Hydrochloride in Prefilled Syringes. J Obstet Gynaecol Can. 2016;38(10):936-944.e3.  (667.48 KB)
Gordon R, Magee LA, Payne BA, Firoz T, Sawchuck D, Tu D, et al.. Magnesium sulphate for the management of preeclampsia and eclampsia in low and middle income countries: a systematic review of tested dosing regimens. J Obstet Gynaecol Can. 2014;36(2):154-163.  (1.42 MB)
De Silva D, Synnes A, von Dadelszen P, Lee T, Bone J, Magee LA. MAGnesium sulphate for fetal neuroprotection to prevent Cerebral Palsy (MAG-CP)-implementation of a national guideline in Canada. Implement Sci. 2018;13(1):8.  (1.89 MB)
Teela K, De Silva D, Chapman K, Synnes A, Sawchuck D, Basso M, et al.. Magnesium sulphate for fetal neuroprotection: benefits and challenges of a systematic knowledge translation project in Canada. BMC Pregnancy Childbirth. 2015;15:347.  (549.75 KB)
Bickford C, Magee LA, Mitton C, Kruse M, Synnes A, Sawchuck D, et al.. Magnesium sulphate for fetal neuroprotection: a cost-effectiveness analysis. BMC Health Serv Res. 2013;13:527.  (2 MB)
Magee LA, Sawchuck D, Synnes A, von Dadelszen P, Basso M, Crane J, et al.. Magnesium Sulphate for Fetal Neuroprotection. Journal of Obstetrics and Gynaecology Canada. 2011;33(5):516 - 529.  (298.54 KB)
De Silva D, Sawchuck D, von Dadelszen P, Basso M, Synnes A, Liston R, et al.. Magnesium Sulphate for Eclampsia and Fetal Neuroprotection: A Comparative Analysis of Protocols Across Canadian Tertiary Perinatal Centres. J Obstet Gynaecol Can. 2015;37(11):975-87.  (362.1 KB)

Pages